New immunotherapy combo targets Hard-to-Treat cancers
NCT ID NCT06680739
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing two immunotherapy drugs, durvalumab and tremelimumab, alone or together, in 60 people with colorectal or endometrial cancer. The goal is to see if these drugs can shrink tumors or slow cancer growth. The study focuses on patients with different genetic types of tumors (MSI-high and MSS) to better understand who might benefit.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab and tremelimumab (immunotherapy drugs)
What this could lead to
If successful, this could point toward a more effective immunotherapy approach for hard-to-treat colorectal and endometrial cancers.
What could go wrong
This is a small, early-phase trial (60 participants) and may not show strong results. Immunotherapy can cause immune-related side effects, and not all patients respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Vall d'Hebron Institute of Oncology
RECRUITINGBarcelona, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact